OncoMatch/Clinical Trials/NCT03368651
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Is NCT03368651 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for hepatocellular carcinoma.
To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior treatment (including interferon)
not previous treated for tumor; be treated before (interferon included)
Lab requirements
Blood counts
neutrophil count≥2.0×10^9/L; hemoglobin≥100g/L; platelet count≥75×10^9/L; PT≤upper limit of normal plus 4 seconds; INR≤2.2
Kidney function
serum creatine<1.5-times upper limit of normal
Liver function
serum albumin≥35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal
the lab test could meet: neutrophil count≥2.0×10^9/L; hemoglobin≥100g/L; platelet count≥75×10^9/L; serum albumin≥35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify